The University of Glasgow and Kadans Science Partner, supported by Scottish Enterprise, are delighted to announce the construction of a new Health Innovation Hub in Govan, setting the stage for a thriving life sciences cluster in the area.
Work on the new Health Innovation Hub has begun, and is due for completion in summer 2025. Morrison Construction have been appointed as the main contractor. The Hub will attract new innovative businesses into the area, and deliver local benefits to the community through job creation.
The Hub is a flagship investment within the University’s Glasgow Riverside…
Fundraise led by Sofinnova Partners, F-Prime Capital, Digitalis Ventures and Cambridge Innovation Capital with participation from Sanofi Ventures and the University of Cambridge Venture Fund
Unique transgenic mouse platform harnesses natural power of T cells to build a portfolio of first-in-class cancer medicines
15 November 2023; Cambridge, England – T-Therapeutics (“the Company”), a biotechnology company developing next-generation TCR therapeutics designed to reshape the clinical landscape for cancer patients, today announces it has raised £48 million ($59 million) in a Series A…
Appointment of Big Pharma executive strengthens leadership team to drive ambitious growth strategy
Coventry, UK, 10 November 2023: NanoSyrinx, a synthetic biology company developing a novel platform for targeted intracellular delivery of biologic therapeutics, today announced Anthony Johnson, M. D., has joined its Board as Non-Executive Director. Tony’s appointment forms part of the Company’s ongoing strategy to expand and strengthen its leadership team as the Company prepares for the next stage in its development.
Most recently, Tony held the position of Chief Executive Officer at Goldfinch…
Tessellate BIO, an Emerging Precision Oncology Company Announces the Appointment of World-Leading Scientists to its Scientific Advisory Board
Amsterdam, the Netherlands and London, UK – 15 November 2023 - Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, today announces the appointment of multiple international experts to its Scientific Advisory Board.
A key part of Tessellate BIO’s strategy is to source cutting-edge research from international world-renowned laboratories to bring into its drug discovery programs. The SAB plays an…
ViaNautis Bio announces $25 million Series A financing to drive the next generation of genetic nanomedicines
- ViaNautis’s proprietary drug delivery platform polyNaut® is designed to deliver genetic therapeutic payloads across difficult-to-penetrate biological barriers, developing new medicines for diseases with unmet clinical need
- Series A led by 4BIO Capital, BGF, and UCB Ventures with participation from the Cystic Fibrosis Foundation, Eli Lilly and Company and existing investors including Origin Capital, Meltwind and O2H
Cambridge UK, 13 November 2023 – ViaNautis…
The experienced life science logistics company, Biocair, provides critical logistics support to a cutting-edge research project into drugs that can treat, and prevent, one of the world’s more serious medical conditions, fibrosis.
Biocair is supporting the innovative, UK-based contract research company, FibroFind, to deliver precious project samples from its pre-clinical research studies to pharmaceutical companies across the world. So far, Biocair has accomplished over 100 rapid, reliable sample deliveries worldwide for FibroFind.
Fibrosis, which can affect most organs in the body, is…
Cambridge Life Sciences is the trusted name in in vitro diagnostic assay kits and we are delighted to be showcasing them at Medica 2023 on the UK Pavilion in Hall 16.
We have 4 key product kits – Paracetamol Assay, Salicylate Assay, Endosc-Hp® Rapid Urease Test and Autozyme® autoimmune kits.
“With our products being trusted in the UK’s highly renowned NHS for over 40 years, we are seeking to find new distributors to get us known across Europe and Medica is the ideal place to meet with them.” said John Gannon, Chief Commercial Officer”.
He continues “Our R&D and manufacturing facilities…
~ Company also ranked amongst 100 Best Companies for Women twice in a row
Mumbai, 3rd Nov, 2023: Thermo Fisher Scientific in India has once again been recognized with two prestigious awards, strengthening its position as a leading workplace in the country. The company has been certified as a Great Place to Work by the Great Place to Work Institute for the fifth consecutive year and ranked among the 100 Best Companies for Women in India for the second year in a row by Avtar and Seramount.
These recognitions demonstrate Thermo Fisher’s dedication to fostering a people-centric…
Key senior appointment to drive research and development activities for portfolio of PhysioMimix OOC microphysiological systems
Cambridge, UK, 02 November 2023: CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced it has appointed Neil Rumbelow as Director of Product Development.
Within the past year, CN Bio has made a series of leadership appointments to support delivery of its ambitious growth strategy across key global markets, in response to rising demand for the Company’s OOC solutions…
Arecor Therapeutics plc
(“Arecor” or the “Company”)
INHIBRX MILESTONE TRIGGERS PAYMENT TO ARECOR UNDER LICENSE AGREEMENT
Cambridge, UK, 2 November 2023. Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces the triggering of a milestone payment from Inhibrx Inc. (“Inhibrx”), for a novel enhanced formulation of INBRX-101, developed by Arecor using the Company’s patented technology, Arestat™, under a license agreement entered into by the two companies in December 2020.
Under the terms of the license agreement, Arecor…